BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors.
Raphael ColleSara LonardiMarine CachanadoMichael J OvermanElena ElezMarwan G FakihFrancesca CortiPriya JayachandranMagali SvrcekAntoine DardenneBaptiste CervantesAlex DuvalRomain CohenFilippo PietrantonioThierry AndréPublished in: The oncologist (2023)
In this cohort, RAS/BRAFV600E mutations were not associated with survival while LS conferred an improved PFS.